News and Trends 23 May 2017 Merck to Pay Ablynx €15M for Getting a Second Nanobody ready for the Clinic Ablynx is receiving its first milestone payment from a deal with Merck for the development of first-in-class treatments for osteoarthritis. Belgium-based Ablynx develops nanobodies, molecules with the same properties as antibodies but with the advantage of being much smaller. This technology has attracted top pharma partners like AbbVie, MSD, Boehringer Ingelheim and Novartis. Now, the third […] May 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Mar 2017 Merck Outsources the Development of its Nanobody for Psoriasis Merck has signed a new agreement with Avillion for its nanobody against psoriasis. Avillion will advance the nanobody from Phase II through Phase III. As part of several partnerships between Merck and the unbeaten nanobody biotech Ablynx, Merck recently cleared Phase Ib with its llama-inspired nanobody targeting the cytokines IL-17 A/F for the treatment of plaque psoriasis. The antibody […] March 30, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Best in Biotech 15 Mar 2017 What are the Best Countries to Recruit Biotech Talents in 2017? Before the “who to recruit” phase, an important question is “where?” We ran through the top countries in which to look for talent in biotech and had a look at what you can expect from each cluster. For each one of them, we also referenced some data on the biotech, life science and research ecosystems to […] March 15, 2017 - 10 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2017 An Antibody to reduce Hospitalizations of Children starts Phase IIb trials Ablynx has treated its first patient in a new trial targeting RSV infections, the main cause of children hospitalizations. Ablynx, one of the few European biotechs that made it into JP Morgan this year, develops nanobodies derived from llamas. The Belgian company announced yesterday that its candidate ALX-0171 has entered testing in Phase IIb as a treatment […] January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 11 Jan 2017 UPDATE: The 5 Hottest European Biotechs in 2017 according to JP Morgan The world’s biggest biotech investor conference, hosted by JP Morgan, is now underway in San Francisco, and European companies are putting up a strong showing. Here are those (in chronological order) who made the cut to present at this invite-only event. We’ll update the post as companies present! While uniQure has hit a number of rough […] January 11, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email